Keros Therapeutics, Inc. (KROS)
Largest Insider Buys in Sector
KROS Stock Price History Chart
KROS Stock Performance
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing …
Insider Activity of Keros Therapeutics, Inc.
Over the last 12 months, insiders at Keros Therapeutics, Inc. have bought $0 and sold $22M worth of Keros Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Keros Therapeutics, Inc. have bought $46.18M and sold $15.67M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 120,000 shares for transaction amount of $6M was made by Kariv Tomer () on 2020‑11‑17.
List of Insider Buy and Sell Transactions, Keros Therapeutics, Inc.
| 2024-08-13 | Sale | director | 250,000 0.6566% | $44.01 | $11M | 0.00% | ||
| 2024-08-13 | Sale | director | 250,000 0.6566% | $44.01 | $11M | 0.00% | ||
| 2023-11-04 | Sale | Chief Financial Officer | 40,000 0.1912% | $45.29 | $1.81M | +0.36% | ||
| 2023-06-09 | Sale | Chief Financial Officer | 20,000 0.073% | $45.42 | $908,367 | -6.61% | ||
| 2023-06-08 | Sale | Chief Financial Officer | 20,000 0.0688% | $47.79 | $955,872 | -16.16% | ||
| 2022-07-15 | Sale | Chief Scientific Officer | 46,034 0.1768% | $30.00 | $1.38M | +44.95% | ||
| 2022-07-13 | Sale | Chief Scientific Officer | 1,916 0.0075% | $30.00 | $57,480 | +48.06% | ||
| 2022-05-11 | Sale | Chief Scientific Officer | 944 0.004% | $42.49 | $40,111 | +3.60% | ||
| 2022-04-11 | Sale | Chief Scientific Officer | 559 0.0024% | $64.15 | $35,860 | -29.72% | ||
| 2022-04-06 | Sale | Chief Operating Officer | 1,728 0.007% | $65.00 | $112,320 | -33.79% | ||
| 2022-04-04 | Sale | Chief Scientific Officer | 7,950 0.0315% | $60.00 | $477,000 | -30.15% | ||
| 2022-04-01 | Sale | Chief Operating Officer | 366 0.0015% | $57.97 | $21,217 | -25.78% | ||
| 2022-03-11 | Sale | Chief Scientific Officer | 875 0.0038% | $54.54 | $47,723 | -11.26% | ||
| 2022-02-11 | Sale | Chief Scientific Officer | 2,650 0.0112% | $52.06 | $137,965 | -10.70% | ||
| 2022-01-11 | Sale | Chief Scientific Officer | 2,650 0.0109% | $53.75 | $142,447 | -16.23% | ||
| 2022-01-05 | Sale | director | 4,034 0.0174% | $58.25 | $234,991 | -18.81% | ||
| 2022-01-05 | Sale | Chief Scientific Officer | 2,650 0.0118% | $60.00 | $159,000 | -18.81% | ||
| 2022-01-04 | Sale | director | 20,062 0.082% | $57.55 | $1.15M | -21.81% | ||
| 2022-01-03 | Sale | director | 23,555 0.0959% | $58.01 | $1.37M | -22.56% | ||
| 2021-12-15 | Sale | Chief Scientific Officer | 735 0.003% | $50.00 | $36,750 | -11.75% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | director | 119522 0.3185% | $66.52 | 1 | 1 | +122.73% |
| GORDON CARL L | director | 119522 0.3185% | $66.52 | 1 | 1 | +122.73% |
| Kariv Tomer | 2288151 6.0981% | $66.52 | 2 | 0 | +51.74% | |
| Nussbaum Ran | 2288151 6.0981% | $66.52 | 2 | 0 | +51.74% | |
| Pontifax Management 4 G.P. (2015) Ltd. | 10 percent owner | 2288151 6.0981% | $66.52 | 2 | 0 | +51.74% |
Institutional Investor Ownership
| Fidelity Investments | $332.23M | 13.91 | 5.02M | +29.54% | +$75.75M | 0.02 | |
| BlackRock | $143.39M | 6 | 2.17M | +6.34% | +$8.55M | <0.01 | |
| Alkeon Capital Management Llc | $105.85M | 4.43 | 1.6M | +6.67% | +$6.62M | 0.58 | |
| State Street | $103.46M | 4.33 | 1.56M | +48.23% | +$33.66M | <0.01 | |
| The Vanguard Group | $102.33M | 4.28 | 1.55M | +7.93% | +$7.52M | <0.01 |